CUE
Cue Biopharma, Inc.
There isn't enough reported data to score CUE yet.
CUE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
CUE's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CUE PE Valuation
CUE has no meaningful PE right now: it lost money over the past year.
CUE Forward outlook
There aren't enough analyst estimates for CUE to show an outlook.
CUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$25.82 | -$9.92 |
| Q1 2026 | -$4.38 | +$14.82 |
| Q4 2025 | -$8.40 | +$13.20 |
| Q3 2025 | -$12.90 | +$14.40 |
| Q2 2025 | -$15.90 | +$13.50 |
| Q1 2025 | -$19.20 | +$12.90 |
| Q4 2024 | -$21.60 | +$11.70 |
| Q3 2024 | -$27.30 | +$8.40 |
CUE is still losing money, but far less than before: $25.82 per share over the past year, against $57.00 at its worst in late 2019.
CUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.9M | +167% |
| Q1 2026 | $5.7M | +1251% |
| Q4 2025 | $21.9M | +1292% |
| Q3 2025 | $2.1M | -36% |
| Q2 2025 | $3M | +11% |
| Q1 2025 | $421K | -75% |
| Q4 2024 | $1.6M | -13% |
| Q3 2024 | $3.3M | +59% |
CUE's revenue is growing: $8M last quarter, up 167% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1113% | -821 points |
| Q1 2026 | -94% | +2827 points |
| Q4 2025 | 9% | +620 points |
| Q3 2025 | -353% | -89 points |
| Q2 2025 | -292% | +98 points |
| Q1 2025 | -2921% | -2184 points |
| Q4 2024 | -611% | +148 points |
| Q3 2024 | -264% | +280 points |
CUE's operating margin was −1113% last quarter, down 821 points from the same quarter a year ago.
CUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29M | -$25.6M |
| Q1 2026 | -$11.1M | -$2.7M |
| Q4 2025 | -$1.1M | +$8M |
| Q3 2025 | -$9M | -$1.5M |
| Q2 2025 | -$3.4M | +$6.6M |
| Q1 2025 | -$8.3M | +$1.5M |
| Q4 2024 | -$9M | +$1.9M |
| Q3 2024 | -$7.5M | +$273K |
CUE has burned cash in almost every quarter: −$50M over the past year, against −$28M the year before.
CUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +1.5M shares |
| 1 year | +99% | +3.2M shares |
| 3 years | +325% | +4.8M shares |
| 5 years | +509% | +5.3M shares |
| Available history | +747% | +5.6M shares |
CUE has 6M diluted shares, up 99% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $127 |
| Q3 2022 | $9,000 |
| Q2 2022 | — |
| Q1 2022 | $191,000 |
CUE Net Leverage
CUE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 12.2 | Oversold |
CUE's weekly RSI is 44 (neutral) and its Stochastic is 12 (oversold).
CUE PE vs Healthcare Sector
CUE has no meaningful PE right now: it lost money over the past year.
CUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.1 | 21% below |
| 20 week MA | $26.9 | 35% below |
| 50 week MA | $20.1 | 13% below |
| 100 week MA | $23.3 | 25% below |
| 200 week MA | $46.7 | 63% below |
CUE is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
CUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $524.1 | $393.6 | -25% |
| 2021 | $393.6 | $373.2 | -5.2% |
| 2022 | $373.2 | $82.5 | -78% |
| 2023 | $82.5 | $79.2 | -4% |
| 2024 | $79.2 | $31.2 | -61% |
| 2025 | $31.2 | $9.74 | -69% |
| 2026 YTD | $9.74 | $17.5 | +80% |
CUE has finished every year since 2020 lower, and it's up 80% so far in 2026.